FDA Drafts CBD Product Guidelines

The rise of CBD popularity–especially during the COVID-19 pandemic–has a number of citizens, authorities, and policymakers concerned. This is because very few regulations are in place to ensure the safety or quality standards of CBD products. And in fact, an FDA study found that many CBD products are markedly off in how much CBD and THC are present in CBD products.

All that is about to change.

In the middle of July, the Food and Drug Administration (FDA) finally published a draft guidance on developing cannabis-based drugs.

The guidance is limited to the development of human CBD drugs and does not cover other products, such as edibles, beverages, and gummies. The FDA is still developing regulations that allow CBD to be marketed as a food item or dietary supplement.

Instead, the guidance emphasizes safety and quality procedures, such as where companies may obtain cannabis for their product and providing proof of a consistently manufactured quality product.

The guidelines have separate sections for cannabis derived from marijuana and hemp, each with their own regulations.

While these guidelines are a step in the right direction, the FDA has a long way to go before finalizing and enforcing them. Until then, it’s important to perform routine and randomized drug testing with your employees, especially if an employee appears intoxicated.

At Nationwide Drug Testing Service, our staff is not only understanding and considerate, but knowledgeable as well. From the moment you contact us, you can expect to deal with a professional, well-trained Representative who will be with you throughout the entire process.

Nationwide Drug Testing Services is one of the largest accredited drug testing networks in the U.S. We offer testing in every state Nationwide, for affordable, Same-Day-Appointment Drug Testing and Fast, Accurate results.

Call us today at 877.497.1002 or Order a Test Online!